Investor directory

Temasek Holdings

Temasek Holdings, established in 1974 and based in Singapore, is an investment company managing a diversified portfolio valued at approximately S$242 billion. The firm actively invests across various sectors, including telecommunications, media and technology, financial services, transportation, consumer products, real estate, life sciences, and energy. Temasek focuses on long-term investment themes such as transforming economies, growing middle-income populations, deepening comparative advantages, and supporting emerging champions. Its investment strategy encompasses a combination of liquid assets, listed and unlisted equities, and private equity opportunities, with a notable emphasis on mid-stage technology and life sciences investments through its private equity arm, Temasek Capital Management. Furthermore, Temasek aims to be the preferred investor for companies in Singapore and internationally, reflecting its commitment to global investment opportunities.
http://www.temasek.com.sg
https://crunchbase.com/organization/temasek
https://facebook.com/temasekholdings
https://linkedin.com/company/temasek-holdings
https://pitchbook.com/profiles/advisor/11313-73
https://twitter.com/temasek
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=574326704
https://www.privateequityinternational.com/database/#/profile?id=1382

Pradyumna Agrawal

Director

Soyoun Ahn

Managing Director, Investment (Credit and Hybrid Solutions)

Gary Ang

Managing Director, Macro Strategy

Parimal Aswani

Managing Director, Technology

Ravi Balasubramanian

Managing Director, Portfolio Development, New Energy and Industrials

Siddartha Bhattacharjee

Head of Mobility and Logistics and Managing Director of Portfolio Strategy & Risk Group

Eric Bielke

Director

Wendy Chandra

Managing Director, Technology

Yuliang Chang

Managing Director, Investment (China)

Eu Chua

Managing Director, Institutional Relations and Singapore Market

Ranjit Dandekar

Managing Director, Investment

Promit Ghosh

Managing Director

Reena Kanagasingam

Managing Director, Investment (Public Markets)

Ming Pey Lim

Chief of Staff, Executive Office, Deputy Chief Corporate Officer and Managing Director, Strategy Office

Sheau Ming Lim

Director

Paul Liu

Managing Director, Investment (Financial Services), Portfolio Strategy and Risk Group

Anuj Maheshwari

Head, Agri-Food Managing Director, Investment (Middle East and Africa)

Nicolas Meier

Managing Director, Investment (EMEA) and Director

Jingwen Miao

Managing Director, Investment (China)

Suranjan Mukherjee

Managing Director, Cross Asset Macro Portfolio and Joint Head, Public Market Investment Strategies

Jonathan Popper

Managing Director, Portfolio Development Group

Ryan Rakestraw

Director

Parangam Ray

Managing Director, Organisation and People

Pierce Scranton

Managing Director, Institutional Relations and Deputy Head, North America

Shaun Seow

Managing Director, Singapore Market and Head, Community Stewardship

Rohit Sobti

Managing Director, New Energy and Industrials

Jason Sun

Chief Representative, Beijing and Managing Director, Investment (China)

Belinda Tan

Managing Director, Finance (Financial Management)

Man-Keung Tang

Managing Director, Macro Strategy

Sulian Tay

Operating Partner

Alan Thompson

Operating Partner

Karen Toh

Managing Director, Finance (Treasury)

Damien Vacherot

Director

Benoit Valentin

Senior Managing Director EMEA and Head of Private Equity Fund Investments

Rob Williams

Managing Director, Investment (EMEA)

Ye Xu

Managing Director, Investment (China)

Past deals in Diversified

Perfection Fresh Australia

Venture Round in 2022
Operator of a fresh produce business based in Sydney, Australia. The company owns farms across the country, including glasshouses, grapes, citrus and berry farms, thereby providing its clients with fresh fruits and vegetables.

D3 Bio

Series A in 2020
D3 Bio Inc. is a biotechnology company founded in 2020 and based in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company adopts a unique approach to medicine development by first identifying significant unmet patient and market needs, particularly in areas where current treatments are inadequate. This understanding informs their research and guides the selection of appropriate scientific and technological methods to define their drug development strategy. Through this differentiated approach, D3 Bio aims to address critical health challenges and improve clinical outcomes for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.